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Edited by Laszlo NagyAbstract The liver X receptors (LXRa and b) are nuclear
receptors that coordinate carbohydrate and lipid metabolism. In-
sight into the physiologic roles of the LXRs has been greatly
facilitated by the discovery of potent synthetic agonists. Here
we show that one of these compounds, T0901317, is also a
high-aﬃnity ligand for the xenobiotic receptor pregnane X recep-
tor (PXR). T0901317 binds and activates PXR with the same
nanomolar potency with which it stimulates LXR activity.
T0901317 induces expression not only of LXR target genes,
but also of PXR target genes in cells and animals, including
the scavenger receptor CD36, a property not shared by more spe-
ciﬁc LXR ligands, such as GW3965. Activation of PXR targets
may explain why T0901317 induces dramatic liver steatosis,
while GW3965 has a milder eﬀect. These results suggest that
many of the biological activities heretofore associated with
LXR activation may be mediated by PXR, not LXR. Since
T0901317 has been widely used in animals to study LXR func-
tion, the in vivo eﬀects of this compound ascribed to LXR activa-
tion should be re-examined.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Ligand1. Introduction
The liver X receptors (LXRa and b; NR1H3, NR1H2) are
nuclear receptors whose endogenous ligands are oxysterols
[1–3]. Expression of LXRa is restricted to liver, intestine, adi-
pose tissue, and macrophages, while LXRb is broadly ex-
pressed [4]. The LXRs are thought to function as sensors of
excessive accumulation of intracellular oxysterols. Ligand-
mediated activation of LXR sets in motion a program of gene
expression aimed at limiting buildup of pathogenic forms of
cholesterol by modulating cholesterol absorption, transport,
excretion, and eﬄux [5]. The LXRs also play a critical roleAbbreviations: LXR, liver X receptor; PXR, pregnane X receptor;
ABCA1, ATP-binding cassette A1; SREBP, sterol-regulated-element
binding protein
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in liver and peripheral tissues [6–9]. This may be related to
their recently described ability to bind glucose [10]. In addi-
tion, LXR activators have signiﬁcant anti-inﬂammatory activ-
ity and LXRa plays an important role in native immunity [11–
13].
Because oxysterols have relatively low aﬃnity for the LXRs
and can have multiple eﬀects in vivo, the study of LXR biology
has relied heavily on genetic mutants and the use of high aﬃn-
ity synthetic ligands. The LXRa/b dual agonists T0901317 and
GW3965 have been widely utilized as non-steroidal chemical
tools to explore the evolving biology of the LXRs [6,14]. These
compounds have been used to establish that pharmacological
activation of LXRs can have therapeutic eﬀects in atheroscle-
rosis, type 2 diabetes, and diseases with an inﬂammatory com-
ponent [8,9,15–19].
While the sulfonamide T0901317 and the tertiary amine
GW3965 elicit many of the same eﬀects in animals, it has be-
come evident that in spite of similar pharmacokinetic and
receptor activation properties, these compounds behave some-
what diﬀerent in vivo. In particular, treatment with T0901317
induces a dramatic increase in hepatic lipogenesis that results
in liver steatosis and serum hypertriglyceridemia [20,21]. Treat-
ment with GW3965 has considerably milder eﬀects; in mice,
chronic treatment does not lead to pathological elevation of
circulating triglycerides [15,22]. A potential explanation for
the diﬀerential behavior of these compounds is that
T0901317 has been shown to activate the bile acid receptor
FXR (NR1H4), another nuclear receptor that plays an impor-
tant role in lipid and glucose metabolism [23,24].
More recently, it has been shown that activation of the nu-
clear receptor pregnane X receptor (PXR, the xenobiotics
receptor) can result in hepatic lipid accumulation [25–27]. This
eﬀect is seen in the absence of an increase in sterol regulatory
element-binding protein lc (SREBP-lc) activity. SREBP-lc is a
primary transcriptional regulator of fatty acid synthesis whose
expression requires LXR. PXR-mediated lipid accumulation
appears to result instead from increased expression of the fatty
acid transporter CD36, a direct PXR target, and enhanced
expression of accessory lipogenic enzymes, such as stearoyl-
CoA desaturase-1 (SCD-1). To examine whether the exacer-
bated lipogenic eﬀects of T0901317 are due to simultaneous
activation of LXR and PXR pathways, we have tested the abil-
ity of this compound to act as a PXR ligand. We ﬁnd that
T0901317 is a potent and eﬃcacious PXR ligand in vitro
and in vivo. Because this compound has been used extensively
to study LXR function, our ﬁndings indicate that conclusionsblished by Elsevier B.V. All rights reserved.
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should be re-examined to consider the possibility that PXR
activation may be involved.2. Materials and methods
2.1. Transcriptional assays
Expression constructs for chimeric nuclear receptors (SXR, PXR,
FXR, and LXRs) were generated by fusing the ligand-binding domains
(LBDs) to the DNA binding domain of yeast GAL4 and inserting
them into pCDNA3 (Invitrogen). Expression constructs were cotrans-
fected with a p4xUAS-luciferase reporter. Assays were validated using
known ligands. 293T cells were cultured in DMEM with 5% FBS. For
transcriptional assays, cells were plated in 384 well plates in DMEM
with 10% fetal bovine lipoprotein deﬁcient serum (FBLDS, Intracel)
in the presence of 7.5 lM lovastatin and 100 lM mevalonic acid. Cells
were transfected using FuGENE 6 (Roche). 24 h later, ligands were
added as 12-point dose response curves starting at 10 lM for
GW3965, T0901317 (Cayman Chemicals), and (E)-4-[2-(5,6,7,8-tetra-
hydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1-propenyl] benzoic acid
(TTNPB, Sigma), 30 lM for pregnenolone 16a-carbonitrile PCN (Sig-
ma) and 100 lM for rifampicin (Sigma). Luciferase activity was read
16 h later.
2.2. Fluorescence–resonance energy transfer assay
FRET assay was performed in 384 well plates in a 20 ll ﬁnal volume.
A mix of 20 nM His-tagged hPXR (Invitrogen), 300 nM biotinylated
SRC-1 peptide (Biotin-CPSSHSSLTERHKILHRLLQEGSPSC-OH),
Europium-labeled anti-His antibody (Perkin–Elmer) and allophycocy-
anin-labeled streptavidin (Prozyme) was prepared. Ligands were tested
in 12-point dose response curves starting at 10 lM for GW3965 and
T0901317, 30 lM for PCN and 100 lM for rifampicin. Plates were
incubated for 1 h at 37 C and FRET was read on an AnalystGT
(Molecular Devices).Fig. 1. T0901317 regulates PXR activity. 293T cells were transfected with a
chimeric fusions of the GAL4 DBD and the ligand binding domain of the ind
for 24 h. Luciferase values are expressed as fold induction vs. DMSO; error2.3. Scintillation proximity assay
SPA was performed as in Janowski et al. [28]. Scintillant-ﬁlled beads
(Amersham) were diluted in SPA buﬀer (10 mM K2HPO4, 10 mM
KH2PO4, 2 mM EDTA, 50 mM NaCl, lmM DTT, 2 mM CHAPS,
10% glycerol) to a ﬁnal concentration of 5 mg/ml. Assay was per-
formed in 384 well plates (Packard) in 20 ll containing beads
(0.2 mg per well) and His-tagged hPXR LBD (200 ng per well).
Amount of protein did not deplete ligand concentration. Binding of
[3H]-T0901317 was tested as a 12-point dilution curve starting at
10 lM. Displacement assays used 30 nM of [3H]-T0901317 (Amer-
sham). Ligands were tested in 12-point dose response curves starting
at 10 lM for GW3965 and T0901317, 30 lM for PCN, and 100 lM
for rifampicin. Plates were shaken for 3 h at room temperature and
read in a Packard Topcount at 1 min per well. Wells devoid of compet-
itor represented 100% binding. Non-speciﬁc binding was measured by
leaving hPXR protein out of the SPA reaction.
Dose response and competition curves were generated by non-
linear regression analysis using GraphPad Prism and the apparent
equilibrium association/dissociation constants (Kd and Ki values)
were determined using the method described by DeBlasi and colleagues
[29].2.4. Gene expression analysis
HepG2 cells were cultured in DMEM with 10% FBS. For gene
expression analysis, cells were plated in DMEM with 10% fetal bovine
lipoprotein deﬁcient serum (FBLDS, Intracel) in the presence of
7.5 lM lovastatin and 100 lM mevalonic acid and treated overnight
with vehicle, or 1 and 10 lM GW3965, T0901317, rifampicin, or
PCN.
RNA was prepared using Nucleospin 96 RNA kits (Macherey-
Nagel). Gene expression was analyzed by TaqMan qRT-PCR using
the one-step Superscript III platinum reagent (Invitrogen). Samples
were run in triplicate as multiplexed reactions with a normalizing
internal control (36B4). Probe and primer sequences are available on
request. Statistical analysis was performed by using a two-tailed
Student’s t-test.GAL4-responsive luciferase reporter and expression plasmids encoding
icated nuclear receptors. Transfected cells were treated with compounds
bars indicate s.d.
Fig. 2. T0901317 is a direct agonist of hPXR. (A) T0901317, but not GW3965, induces recruitment of SRC-1 to the hPXR LBD. Note that T0901317
is as eﬃcacious as rifampicin. Values are presented as fold induction vs. vehicle. Error bars represent standard deviation of two experiments analyzed
in triplicate. (B) [3H]-T0901317 can bind hPXR in a scintillation proximity assay. (C) T0901317 and rifampicin compete for hPXR binding and
eﬀectively displace bound [3H]-T0901317 (30 nM) in a SPA assay. Data are expressed as percent binding of labeled compound and represent two
diﬀerent experiments performed in duplicate. Error bars indicate standard deviation.
Fig. 3. T0901317 regulates PXR target genes in vivo. (A) HepG2 cells were treated overnight with T0901317, GW3965, rifampicin, or PCN at 1 and
10 lM and gene expression was evaluated by TaqMan qRT-PCR. T0901317 and GW3965 induce LXRs target genes, but T0901317 also regulates
expression of PXR target genes such as CYP3A and CD36 with similar eﬃcacy to rifampicin. Error bars show standard deviation. *p < 0.05 and
**p < 0.001.
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Ten-week-old male C57BL/6 mice, six animals per group, were
maintained on a standard chow diet. Mice were gavaged daily with
vehicle, T0901317 (50 mpk), or GW3965 (50 mpk) for 3 days before
killed. Mice were fasted overnight prior to the last dose of compound,
and killed 3 h later. Analysis of blood chemistry was performed using
an Olympus Bioanalyzer. All experiments were approved by the Insti-
tutional Animal Care and Use Committee of The Genomics Institute
of the Novartis Research Foundation.3. Results
To understand the diﬀerential eﬀect of T0901317 and
GW3965 on lipid metabolism, we tested whether T0901317
could also modulate the activity of PXR, a nuclear receptor
responsive to xenobiotics that has been recently associated
with hepatic lipid accumulation. Cells were transfected with
a Gal4-responsive promoter and chimeric constructs of the li-
gand-binding domain of several nuclear receptors fused to theFig. 4. Gene expression and lipid proﬁles in mice treated with T0901317 o
GW3965 or T0901317 and hepatic gene expression assessed. (A,B) GW3965 a
eﬀect on lipogenic genes. (C) T0901317 also induces expression of PXR target
aﬀect expression of these genes. (C) Serum triglyceride (TG) and non-esteri
T0901317, but not GW3965. Error bars show standard deviation. *p < 0.05Gal4 DNA binding domain. As previously reported, we ob-
served that T0901317 activated not only LXRa, but also the
bile acid receptor FXR (EC50 = 0.5 lM), albeit with decreased
eﬃcacy (35%) compared to TTNPB (Fig. 1A). Interestingly,
we found that T0901317 activates hPXR with the same po-
tency it modulates the LXRs (EC50: LXRa = 15 nM;
hPXR = 23 nM) and with full eﬃcacy (119%) compared to
the reference compound rifampicin (Fig. 1B). T0901317 also
increased mPXR activity with an EC50 of 0.8 lM. In contrast,
GW3965 induced LXR transcriptional activity but failed to
modulate any other nuclear receptors tested.
To evaluate if T0901317 binds PXR directly, we used a cell-
free FRET-based coactivator recruitment assay. T0901317 in-
duced recruitment of a peptide derived from SRC-1 to the
LBD of hPXR (EC50 = 27 nM) with the same eﬃcacy of as rif-
ampicin, a bona ﬁde hPXR ligand (EC50 = 2 lM). Pregneno-
lone 16a-carbonitrile (PCN, an mPXR-selective ligand) and
GW3965 had no eﬀect. To conﬁrm that T0901317 binds
PXR, a scintillation proximity (SPA) assay was run wherer GW3965. Wild-type mice were treated for three days with vehicle,
nd T0901317 both induce LXR target genes, but T091317 has a greater
genes such as cyp3All, cyp2B10, GST4a, and CD36. GW3965 does not
ﬁed free fatty acids (NEFA) levels are increased in mice treated with
and **p < 0.001.
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beads was tested. [3H]-T0901317 bound hPXR and induced
scintillation with a Kd of 26 ± 3 nM (Fig. 2B). T0901317 and
rifampicin displaced hPXR-bound [3H]-T0901317 with a Ki
of 16 ± 6 nM and 0.9 ± 0.3 lM, respectively, while GW3965
and PCN failed to compete. Together, these ﬁndings indicate
that T0901317 is a potent and eﬃcacious agonist of PXR func-
tion.
To assess if T0901317 can regulate PXR target genes in vivo,
we examined gene expression in HepG2 cells treated with
T0901317 or GW3965. Both compounds induced expression
of LXR target genes (ABCA1, SREBP-lc, FAS, SCD-1) to a
similar degree (Fig. 3). However, T0901317 also induced
expression of the classical PXR target CYP3A4 and of the free
fatty acid transporter CD36, a more recently described PXR
target gene [25]. Furthermore, T0901317 activated PXR target
genes with comparable eﬃcacy to rifampicin. As expected,
PCN had no eﬀect in this human cell line. To explore the phys-
iologic relevance of these ﬁndings, wild-type mice were dosed
with T0901317 and GW3965 (both at 50 mpk daily by oral ga-
vage) for three days and the pattern of hepatic gene expression
analyzed. The pharmacokinetic proﬁle of these two com-
pounds is very similar in the formulation used for delivery
(data not shown). Both GW3965 and T0901317 induced
LXR target genes (e.g. ABCA1, SREBP-lc), but T0901317
upregulated expression of lipogenic genes to a considerably
more dramatic extent (Fig. 4B). In addition, T0901317 pro-
moted expression of the PXR targets CYP3A11, CD36,
GST4a, and CYP2B10 while GW3965 did not (Fig. 4B and
C) [30,31]. These disparities in hepatic gene expression were re-
ﬂected in signiﬁcantly diﬀerent serum lipid proﬁles: T0901317
treatment increased circulating triglycerides six fold and dou-
bled the level of free fatty acids, while GW3965 did not aﬀect
either parameter (Fig. 4C).4. Discussion
Much of the biology of LXR function has been unraveled
with the aid of high aﬃnity synthetic ligands. Here, we have
shown that one of these compounds, T0901317, is also a po-
tent agonist for PXR. T0901317 binds and activates hPXR
and hLXRa with similar aﬃnity, and it can regulate multiple
PXR target genes in human cells and mice with similar eﬃ-
cacy to established PXR ligands, but signiﬁcantly greater po-
tency. Our binding studies are substantiated by the recent
report of a PXR-T0901317 crystal structure [32]. Since in
addition to its role as a xenobiotic sensor responsible for
catabolism of toxic compounds, PXR plays an important role
in lipid, bile acid, and carbohydrate metabolism, our ﬁndings
suggest that some of the eﬀects observed with T0901317 that
have been ascribed to LXR activation may be the result of
simultaneous stimulation of PXR and LXR activity. For
example, the more deleterious increase in lipogenesis and he-
patic lipid accumulation observed with T0901317 as compared
to the LXR-selective ligand GW3965 may reﬂect activation of
PXR target genes that can modulate lipid metabolism, such as
CD36. Because PXR and the LXRs are co-expressed in multi-
ple tissues (e.g., liver, intestine), use of T0901317 under the
assumption that it behaves as an LXR-selective agonist may
have led to some inaccurate conclusions regarding the eﬀects
of LXR activation in vivo. These observations may need tobe re-examined to diﬀerentiate the eﬀects of LXR and PXR
activation.
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